OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
The Novel Class IIa Selective Histone Deacetylase Inhibitor YAK540 Is Synergistic with Bortezomib in Leukemia Cell Lines
Lukas M. Bollmann, Alexander Jan Skerhut, Yodita Asfaha, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 21, pp. 13398-13398
Open Access | Times Cited: 13
Lukas M. Bollmann, Alexander Jan Skerhut, Yodita Asfaha, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 21, pp. 13398-13398
Open Access | Times Cited: 13
Showing 13 citing articles:
Noval advance of histone modification in inflammatory skin diseases and related treatment methods
Lichen Zhang, Rongrong Chai, Zongguang Tai, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 7
Lichen Zhang, Rongrong Chai, Zongguang Tai, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 7
Significance of Five-Membered Heterocycles in Human Histone Deacetylase Inhibitors
Anton Frühauf, Martin Behringer, Franz‐Josef Meyer‐Almes
Molecules (2023) Vol. 28, Iss. 15, pp. 5686-5686
Open Access | Times Cited: 16
Anton Frühauf, Martin Behringer, Franz‐Josef Meyer‐Almes
Molecules (2023) Vol. 28, Iss. 15, pp. 5686-5686
Open Access | Times Cited: 16
Prevention and Health Benefits of Prebiotics, Probiotics and Postbiotics in Acute Lymphoblastic Leukemia
Adrian Martyniak, Zuzanna Zakrzewska, Magdalena Schab, et al.
Microorganisms (2023) Vol. 11, Iss. 7, pp. 1775-1775
Open Access | Times Cited: 15
Adrian Martyniak, Zuzanna Zakrzewska, Magdalena Schab, et al.
Microorganisms (2023) Vol. 11, Iss. 7, pp. 1775-1775
Open Access | Times Cited: 15
HDAC inhibitors: Promising agents for leukemia treatment
Yun Deng, Cheng Qian, Jing He
Biochemical and Biophysical Research Communications (2023) Vol. 680, pp. 61-72
Closed Access | Times Cited: 11
Yun Deng, Cheng Qian, Jing He
Biochemical and Biophysical Research Communications (2023) Vol. 680, pp. 61-72
Closed Access | Times Cited: 11
Microbiome Modulation in Pediatric Leukemia: Impact on Graft-Versus-Host Disease and Treatment Outcomes: A Narrative Review
Samuel Bogdan Todor, Cristian Ichim
Children (2025) Vol. 12, Iss. 2, pp. 166-166
Open Access
Samuel Bogdan Todor, Cristian Ichim
Children (2025) Vol. 12, Iss. 2, pp. 166-166
Open Access
5-(Trifluoromethyl)-1,2,4-oxadiazole (TFMO)-based highly selective class IIa HDAC inhibitors exhibit synergistic anticancer activity in combination with bortezomib
Yodita Asfaha, Lukas M. Bollmann, Alexander Jan Skerhut, et al.
European Journal of Medicinal Chemistry (2023) Vol. 263, pp. 115907-115907
Closed Access | Times Cited: 6
Yodita Asfaha, Lukas M. Bollmann, Alexander Jan Skerhut, et al.
European Journal of Medicinal Chemistry (2023) Vol. 263, pp. 115907-115907
Closed Access | Times Cited: 6
Synergistic Interaction of the Class IIa HDAC Inhibitor CHDI0039 with Bortezomib in Head and Neck Cancer Cells
Christian Schrenk, Lukas M. Bollmann, Corinna Haist, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5553-5553
Open Access | Times Cited: 5
Christian Schrenk, Lukas M. Bollmann, Corinna Haist, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5553-5553
Open Access | Times Cited: 5
Z-ligustilide preferentially caused mitochondrial dysfunction in AML HL-60 cells by activating nuclear receptors NUR77 and NOR1
Gen Liu, Zhigang Chen, Lirong Yang, et al.
Chinese Medicine (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 4
Gen Liu, Zhigang Chen, Lirong Yang, et al.
Chinese Medicine (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 4
Role of histone deacetylase inhibitors in non-neoplastic diseases
Chunxiao Zhou, Dengke Zhao, Chunyan Wu, et al.
Heliyon (2024) Vol. 10, Iss. 13, pp. e33997-e33997
Open Access | Times Cited: 1
Chunxiao Zhou, Dengke Zhao, Chunyan Wu, et al.
Heliyon (2024) Vol. 10, Iss. 13, pp. e33997-e33997
Open Access | Times Cited: 1
Histone Acetyltransferase and Deacetylase Inhibitors—New Aspects and Developments
Hany S. Ibrahim, Wolfgang Sippl
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 23, pp. 16985-16985
Open Access | Times Cited: 2
Hany S. Ibrahim, Wolfgang Sippl
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 23, pp. 16985-16985
Open Access | Times Cited: 2
The Antioxidant and HDAC-Inhibitor α-Lipoic Acid Is Synergistic with Exemestane in Estrogen Receptor-Positive Breast Cancer Cells
Laura S. Pradel, Yu-Lin Ho, Holger Gohlke, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 15, pp. 8455-8455
Open Access
Laura S. Pradel, Yu-Lin Ho, Holger Gohlke, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 15, pp. 8455-8455
Open Access
Triple Combination of Entinostat, a Bromodomain Inhibitor, and Cisplatin Is a Promising Treatment Option for Bladder Cancer
Lukas M. Bollmann, Friedrich Lange, Alexandra Hamacher, et al.
Cancers (2024) Vol. 16, Iss. 19, pp. 3374-3374
Open Access
Lukas M. Bollmann, Friedrich Lange, Alexandra Hamacher, et al.
Cancers (2024) Vol. 16, Iss. 19, pp. 3374-3374
Open Access
Epigenetic Alterations as Vital Aspects of Bortezomib Molecular Action
Piotr Kulig, Karolina Łuczkowska, Estera Bakinowska, et al.
Cancers (2023) Vol. 16, Iss. 1, pp. 84-84
Open Access | Times Cited: 1
Piotr Kulig, Karolina Łuczkowska, Estera Bakinowska, et al.
Cancers (2023) Vol. 16, Iss. 1, pp. 84-84
Open Access | Times Cited: 1
